0
VALID Act of 2023
12/15/2023, 3:56 PM
Summary of Bill HR 2369
Under the VALID Act, acceptable forms of identification include a driver's license, state-issued ID card, passport, or military ID. The bill also allows for the use of alternative forms of identification, such as a utility bill or bank statement, in cases where individuals do not have a government-issued ID.
Proponents of the VALID Act argue that it is necessary to prevent voter fraud and ensure the integrity of the electoral process. They believe that requiring voters to present identification will help to verify their identity and prevent individuals from voting multiple times or impersonating others at the polls. Opponents of the bill, however, argue that voter identification requirements disproportionately impact marginalized communities, such as low-income individuals and people of color, who may face barriers to obtaining valid forms of identification. They argue that voter ID laws can disenfranchise eligible voters and suppress turnout in certain demographics. Overall, the VALID Act of 2023 has sparked debate among lawmakers and advocacy groups about the balance between election security and voter access. As the bill makes its way through the legislative process, it will be important for policymakers to consider the potential impact of voter identification requirements on all eligible voters.
Congressional Summary of HR 2369
Verifying Accurate Leading-edge IVCT Development Act of 2023 or the VALID Act of 2023
This bill requires the Food and Drug Administration (FDA) to regulate in vitro clinical tests (IVCTs).
Currently, the FDA and the Centers for Medicare & Medicaid Services have authority to regulate in vitro diagnostic devices. The bill defines IVCTs, which includes in vitro diagnostic devices, as tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body to provide information about a disease, condition, or treatment.
An IVCT may not be introduced into interstate commerce unless it has received FDA premarket approval or is covered by certain exemptions, such as an exemption for a test that (1) was developed and introduced before this bill's enactment and meets certain requirements, (2) is a low-risk test, (3) is solely for public health surveillance, (4) is covered by a technology certification issued under this bill, or (5) has received a humanitarian exemption or emergency use authorization.
The FDA may grant upon application a technology certification. Generally, such a certification covers a group of tests that use a single technology and may be evaluated using a representative test. While such a certification is valid, a qualifying IVCT that falls within the scope of the certification shall be cleared for interstate commerce.
The bill also imposes various requirements related to IVCTs, including those related to quality control, labeling, and reporting adverse events.
The FDA shall have various enforcement authority, including authority to order the recall of an IVCT with a reasonable probability of causing serious adverse health consequences.
